BMO Capital raises Ionis Pharmaceuticals price target to $61
BMO Capital raised its price target on Ionis Pharmaceuticals to $61.00 per share from $60.00 and maintained its Market Perform rating.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.